Please login to the form below

Not currently logged in

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October


A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the US Food and Drug Administration (FDA), with a decision due by 18 October.

The co-formulation of two of Roche’s blockbuster breast cancer antibodies promises to make administration quicker and easier for patients, and could also help defend the company’s HER2 franchise from encroaching biosimilars.

The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) can be administered by subcutaneous (SC) injection in minutes, compared to hours with intravenous (IV) administration using the current single-agent formulations, says Roche.

The FDA review is based on a phase 3 trial called FeDeriCa, which showed that the combination was non-inferior to the two drugs given separately when it came to achieving therapeutic levels in the blood in HER2-positive breast cancer patients. It also matched the safety and efficacy of the current formulations when given alongside chemotherapy.

At the moment, Herceptin and Perjeta therapy requires a 150-minute infusion to provide a loading dose, followed by 60- to 150-minute maintenance doses, but the new format takes eight minutes for loading and five minutes for maintenance.

“SC administration has been shown to be strongly preferred by the majority of patients compared to IV administration of the same medicine, with the most common reason being that administration required less time in the clinic,” said Roche in a statement.

The Swiss drugmaker already has an SC version of Herceptin monotherapy on the market, but that hasn’t on its own stopped biosimilars of the drug eating into market share. Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum.

The product managed a 9% gain in the US market, which accounts for around 50% of the product’s sales, but for most of 2019 there was no biosimilar competition in that market and sales erosion is expected to gather pace this year.

Amgen launched its Kamjinti there in July, with Biocon and Mylan reaching the market with their Ogivri biosimilar in December, and others are in the latter stages of regulatory review.

Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it improves the efficacy of Herceptin when used in combination.

It remains in patent until 2023 in Europe and 2024 in the US, so Roche is hoping the ease of administration of the fixed-dose combination will discourage patients from using the IV formulation of the drug alongside a Herceptin biosimilar.

Article by
Phil Taylor

25th February 2020

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...